Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Ovarian Yolk Sac Tumors in Older Women Arising From Epithelial Ovarian Tumors or With No Detectable Epithelial Component

Roth, Lawrence M. M.D.; Talerman, Aleksander M.D.; Levy, Tally M.D.; Sukmanov, Oleg M.D.; Czernobilsky, Bernard M.D.

International Journal of Gynecological Pathology: September 2011 - Volume 30 - Issue 5 - p 442–451
doi: 10.1097/PGP.0b013e3182164386
PATHOLOGY OF THE UPPER GENITAL TRACT: ORIGINAL ARTICLES
Buy

Yolk sac tumor (YST) occurs rarely in older women, either in association with a variety of ovarian epithelial tumors or, considerably less often, without an identifiable epithelial precursor. The patients often have elevated serum levels of α-fetoprotein that roughly correlate with the amount of the YST component. In postmenopausal women with an ovarian mass and elevated serum levels of α-fetoprotein, a tumor of this type should be suspected. Endometrioid carcinoma is the most common putative precursor, and the tumor is often associated with an endometriotic cyst; however, malignant Müllerian mixed tumor and mucinous neoplasms have also been reported as precursors. We report 4 cases of YST in postmenopausal women. Of the 3 cases with an identified epithelial component, 1 was serous carcinoma, another was clear cell adenocarcinoma, and the third was an admixture of endometrioid and clear cell adenocarcinoma arising from an endometriotic cyst. Although a precursor epithelial ovarian neoplasm, typically a malignancy (somatic carcinoma), is usually identified, no precursor neoplasm was observed in 1 of our cases and in 5 cases from the literature. We believe that YSTs in older women, whether or not an epithelial component is detected histologically, constitute a single entity that is distinct from YSTs in younger patients and should be treated aggressively. Neoplasms with a YST component in older women are less responsive to the chemotherapy currently used for ovarian germ cell tumors; therefore, adjuvant therapy should include platinum-based chemotherapy designed to treat both epithelial ovarian cancer and germ cell tumors. Of the 24 reported cases, including our own, 17 died of neoplasms within 25 months and another was living with disease at 2 months. However, 2 more recent patients treated aggressively with platinum-based chemotherapy designed to treat both epithelial and germ cell tumor components with stage 1 disease are living and have been disease free >1 year after operation.

Department of Pathology (L.M.R.), Indiana University School of Medicine, Indianapolis, IN

Department of Pathology (A.T.), Thomas Jefferson University, Philadelphia, PA

Division of Gynecologic Oncology (T.L.)

Department of Pathology (O.S.), Wolfson Medical Center, Holon, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv

Patho-Lab Diagnostics (B.C.), Ness-Ziona, Israel

Address correspondence and reprint requests to Lawrence M. Roth, MD, Department of Pathology, Indiana University School of Medicine, Van Nuys Medical Science Building 128, 635 Barnhill Drive, Indianapolis, IN 46202-5120. e-mail: lroth@iupui.edu

©2011International Society of Gynecological Pathologists